第一单位：
Novartis Pharmaceuticals AG, Basel, Switzerland.
作者：
Zufar,Mulyukov [1]
;
Pearse A,Keane [2]
;
Jayashree,Sahni [1]
;
Sandra,Liakopoulos [3]
;
Katja,Hatz [4]
;
Daniel Shu,Wei Ting [5]
;
Roberto,Gallego-Pinazo [6]
;
Tariq,Aslam [7]
;
Chui Ming,Gemmy Cheung [8]
;
Gabriella,De Salvo [9]
;
Oudy,Semoun [10]
;
Gábor Márk,Somfai [11]
;
Andreas,Stahl [12]
;
Brandon J,Lujan [13]
;
Daniel,Lorand [1]
作者单位：
Novartis Pharmaceuticals AG, Basel, Switzerland.
[1]
NIHR Moorfields Biomedical Research Centre, London, United Kingdom.;UCL Institute of Ophthalmology, London, United Kingdom.
[2]
Cologne Image Reading Center and Laboratory, Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.;Department of Ophthalmology, Goethe University, Frankfurt, Germany.
[3]
Vista Augenklinik Binningen, Binningen, Switzerland.;Faculty of Medicine, University of Basel, Basel, Switzerland.
[4]
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.
[5]
Oftalvist Clinic, Valencia, Spain.
[6]
School of Pharmacy and Optometry, University of Manchester, Manchester Royal Eye Hospital, Manchester, United Kingdom.
[7]
Duke-NUS Academic Clinical Programme, University of Singapore, Singapore, Republic of Singapore.;Singapore National Eye Centre, Singapore, Republic of Singapore.
[8]
Ophthalmology Department, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
[9]
Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Institut d'Ophtalmologie du Panthéon, Paris, France.
[10]
Stadtspital Zürich, Department of Ophthalmology, Zürich, Switzerland.;Spross Research Institute, Zürich, Switzerland.;Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
[11]
Department of Ophthalmology, University Hospital Greifswald, Greifswald, Germany.
[12]
OHSU Casey Eye Institute, Portland, Oregon.
[13]
DOI
10.1016/j.xops.2024.100565
PMID
39253548
发布时间
2024-09-11
换一批
换一批
